Procept Biorobotics (PRCT) closed at $20.03 on October 22, 2026, up 9.6% from the previous close, on volume of 1,111,025 shares (30-day average 1,319,895).
Data as of October 22, 2026.
22-Oct-2026
Globe Newswire (Thu, 22-Oct 8:29 AM ET)
PROCEPT BioRobotics to Report Third Quarter 2026 Financial Results on November 4th, 2026
Globe Newswire (Mon, 12-Oct 4:05 PM ET)
PRCT Rises as Law Firm Says Long-Term Holders Since Feb. 27, 2024 May Seek Governance Reforms
Market Chameleon (Mon, 12-Oct 7:32 AM ET)
Globe Newswire (Fri, 9-Oct 11:51 AM ET)
Globe Newswire (Tue, 6-Oct 11:53 AM ET)
PRNewswire (Thu, 1-Oct 9:45 AM ET)
Globe Newswire (Wed, 30-Sep 3:52 PM ET)
Globe Newswire (Tue, 29-Sep 10:19 AM ET)
Globe Newswire (Thu, 24-Sep 9:36 AM ET)
Portnoy Law Firm Announces Class Action on Behalf of PROCEPT BioRobotics Corporation Investors
Globe Newswire (Tue, 22-Sep 12:38 PM ET)
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Procept Biorobotics trades on the NASDAQ stock market under the symbol PRCT.
As of October 22, 2026, PRCT stock price climbed to $20.03 with 1,111,025 million shares trading.
PRCT has a beta of 0.56, meaning it tends to be less sensitive to market movements. PRCT has a correlation of 0.02 to the broad based SPY ETF.
PRCT has a market cap of $1.15 billion. This is considered a Small Cap stock.
Last quarter Procept Biorobotics reported $94 million in Revenue and -$.47 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.01.
In the last 3 years, PRCT traded as high as $103.81 and as low as $16.67.
The top ETF exchange traded funds that PRCT belongs to (by Net Assets): VTI, IWM, VB, VBK, VXF.
PRCT has underperformed the market in the last year with a return of -42.1%, while SPY returned +14.9%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in PRCT shares. However, PRCT has outperformed the market in the last 3 month and 2 week periods, returning +8.2% and +11.8%, while SPY returned +2.3% and -1.7%, respectively. This indicates PRCT has been having a stronger performance recently.
PRCT support price is $17.55 and resistance is $18.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRCT shares will trade within this expected range on the day.
